These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24035338)

  • 1. Discovery of 2,8-diazaspiro[4.5]decane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating hypertension.
    Kato Y; Fuchi N; Saburi H; Nishimura Y; Watanabe A; Yagi M; Nakadera Y; Higashi E; Yamada M; Aoki T
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5975-9. PubMed ID: 24035338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating of chronic kidney diseases.
    Kato Y; Fuchi N; Nishimura Y; Watanabe A; Yagi M; Nakadera Y; Higashi E; Yamada M; Aoki T; Kigoshi H
    Bioorg Med Chem Lett; 2014 Jan; 24(2):565-70. PubMed ID: 24373724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.
    Shen HC; Ding FX; Deng Q; Xu S; Chen HS; Tong X; Tong V; Zhang X; Chen Y; Zhou G; Pai LY; Alonso-Galicia M; Zhang B; Roy S; Tata JR; Berger JP; Colletti SL
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5314-20. PubMed ID: 19682899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.
    Shen HC; Ding FX; Wang S; Xu S; Chen HS; Tong X; Tong V; Mitra K; Kumar S; Zhang X; Chen Y; Zhou G; Pai LY; Alonso-Galicia M; Chen X; Zhang B; Tata JR; Berger JP; Colletti SL
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3398-404. PubMed ID: 19481932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based optimization of cyclopropyl urea derivatives as potent soluble epoxide hydrolase inhibitors for potential decrease of renal injury without hypotensive action.
    Takai K; Nakajima T; Takanashi Y; Sone T; Nariai T; Chiyo N; Nakatani S; Ishikawa C; Yamaguchi N; Fujita K; Yamada K
    Bioorg Med Chem; 2014 Mar; 22(5):1548-57. PubMed ID: 24530032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional rational approach to the discovery of potent substituted cyclopropyl urea soluble epoxide hydrolase inhibitors.
    Takai K; Chiyo N; Nakajima T; Nariai T; Ishikawa C; Nakatani S; Ikeno A; Yamamoto S; Sone T
    Bioorg Med Chem Lett; 2015 Apr; 25(8):1705-1708. PubMed ID: 25800114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats.
    Ghosh S; Chiang PC; Wahlstrom JL; Fujiwara H; Selbo JG; Roberds SL
    Basic Clin Pharmacol Toxicol; 2008 May; 102(5):453-8. PubMed ID: 18312493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
    Anandan SK; Webb HK; Chen D; Wang YX; Aavula BR; Cases S; Cheng Y; Do ZN; Mehra U; Tran V; Vincelette J; Waszczuk J; White K; Wong KR; Zhang LN; Jones PD; Hammock BD; Patel DV; Whitcomb R; MacIntyre DE; Sabry J; Gless R
    Bioorg Med Chem Lett; 2011 Feb; 21(3):983-8. PubMed ID: 21211973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.
    Zhao X; Yamamoto T; Newman JW; Kim IH; Watanabe T; Hammock BD; Stewart J; Pollock JS; Pollock DM; Imig JD
    J Am Soc Nephrol; 2004 May; 15(5):1244-53. PubMed ID: 15100364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of haem oxygenase in the renoprotective effects of soluble epoxide hydrolase inhibition in diabetic spontaneously hypertensive rats.
    Elmarakby AA; Faulkner J; Pye C; Rouch K; Alhashim A; Maddipati KR; Baban B
    Clin Sci (Lond); 2013 Oct; 125(7):349-59. PubMed ID: 23611540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat.
    Sellers KW; Sun C; Diez-Freire C; Waki H; Morisseau C; Falck JR; Hammock BD; Paton JF; Raizada MK
    FASEB J; 2005 Apr; 19(6):626-8. PubMed ID: 15659536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.
    Jones PD; Tsai HJ; Do ZN; Morisseau C; Hammock BD
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5212-6. PubMed ID: 16870439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis.
    Du F; Sun W; Morisseau C; Hammock BD; Bao X; Liu Q; Wang C; Zhang T; Yang H; Zhou J; Xiao W; Liu Z; Chen G
    Eur J Med Chem; 2021 Nov; 223():113678. PubMed ID: 34218083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insight into the binding modes and inhibition mechanisms of adamantyl-based 1,3-disubstituted urea inhibitors in the active site of the human soluble epoxide hydrolase.
    Chen H; Zhang Y; Ye C; Feng TT; Han JG
    J Biomol Struct Dyn; 2014; 32(8):1231-47. PubMed ID: 23815795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential cardiotoxicity in response to chronic doxorubicin treatment in male spontaneous hypertension-heart failure (SHHF), spontaneously hypertensive (SHR), and Wistar Kyoto (WKY) rats.
    Sharkey LC; Radin MJ; Heller L; Rogers LK; Tobias A; Matise I; Wang Q; Apple FS; McCune SA
    Toxicol Appl Pharmacol; 2013 Nov; 273(1):47-57. PubMed ID: 23993975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension.
    Jung O; Brandes RP; Kim IH; Schweda F; Schmidt R; Hammock BD; Busse R; Fleming I
    Hypertension; 2005 Apr; 45(4):759-65. PubMed ID: 15699457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.
    Shen HC; Ding FX; Wang S; Deng Q; Zhang X; Chen Y; Zhou G; Xu S; Chen HS; Tong X; Tong V; Mitra K; Kumar S; Tsai C; Stevenson AS; Pai LY; Alonso-Galicia M; Chen X; Soisson SM; Roy S; Zhang B; Tata JR; Berger JP; Colletti SL
    J Med Chem; 2009 Aug; 52(16):5009-12. PubMed ID: 19645482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of polar spirocyclic orally bioavailable urea inhibitors of soluble epoxide hydrolase.
    Lukin A; Kramer J; Hartmann M; Weizel L; Hernandez-Olmos V; Falahati K; Burghardt I; Kalinchenkova N; Bagnyukova D; Zhurilo N; Rautio J; Forsberg M; Ihalainen J; Auriola S; Leppänen J; Konstantinov I; Pogoryelov D; Proschak E; Dar'in D; Krasavin M
    Bioorg Chem; 2018 Oct; 80():655-667. PubMed ID: 30059891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension.
    Honetschlägerová Z; Husková Z; Vaňourková Z; Sporková A; Kramer HJ; Hwang SH; Tsai HJ; Hammock BD; Imig JD; Červenka L; Kopkan L
    J Physiol; 2011 Jan; 589(Pt 1):207-19. PubMed ID: 21078594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the binding mode of 1, 3, 4-oxadiazole derivatives as amide-based inhibitors for soluble epoxide hydrolase (sEH) by molecular docking and MM-GBSA.
    Karami L; Saboury AA; Rezaee E; Tabatabai SA
    Eur Biophys J; 2017 Jul; 46(5):445-459. PubMed ID: 27928588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.